Track Organogenesis Holdings Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Organogenesis Holdings Inc. ORGO Open Organogenesis Holdings Inc. in new tab

2.24 USD
P/E
15.27
EPS
0.15
P/B
0.97
ROE
9.04
Beta
1.39
Organogenesis Holdings Inc. logo

Organogenesis Holdings Inc.

🧾 Earnings Recap – Q3 2025

Organogenesis Holdings reported strong third quarter results for 2025, driven by a 31% increase in Advanced Wound Care product sales and strategic advancements in Medicare payment reforms, positioning the company favorably for future growth.

  • Q3 revenues exceeded guidance, with Advanced Wound Care sales up 31% year-over-year and Surgical & Sports Medicine sales climbing 25%.
  • The finalization of Medicare physician fee schedules marks a significant development, offering expanded access and potential for higher reimbursement for PMA products.
  • Progress on the ReNu program includes favorable clinical results, FDA RMAT designation, and an upcoming meeting scheduled for December to discuss the BLA submission.
  • The company maintained its competitive edge through strong brand equity and established customer relationships in the evolving skin substitute market.
  • Organogenesis is well-positioned to leverage changes in Medicare policy and drive innovation in regenerative medicine.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 7, 2026
P/E15.27
EPS0.15
Book Value2.36
Price to Book0.97
Debt/Equity18.93
% Insiders47.614%
Growth
Revenue Growth0.78%
Earnings Growth5.55%
Estimates
Forward P/E7.90
Forward EPS0.29

DCF Valuation

Tweak assumptions to recompute fair value for Organogenesis Holdings Inc. (ORGO)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Organogenesis Holdings Inc. Logo Organogenesis Holdings Inc. Analysis (ORGO)

United States Health Care Official Website Stock

Is Organogenesis Holdings Inc. a good investment? Organogenesis Holdings Inc. (ORGO) is currently trading at 2.24 USD.

In terms of valuation, the stock trades at a P/E ratio of 15.27. This valuation is generally in line with the broader market.

Earnings Schedule: Organogenesis Holdings Inc. is expected to release its next earnings report on May 7, 2026. The market consensus estimate for Forward EPS is 0.29.

Investor FAQ

Does Organogenesis Holdings Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Organogenesis Holdings Inc.?

Organogenesis Holdings Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 7, 2026. The company currently has a trailing EPS of 0.15.

Company Profile

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.

Exchange Ticker
NMS (United States) ORGO
FRA (Germany) 2PQ.F

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion